Speaking on the above topic is Mr Satish Jindal, Vice President & Managing Director
Biocon-BMS Research Center, India. He will be presenting at Drug Discovery World Asia 2012, part of a series of conferences at 5th Annual BioPharma Asia Convention 2012.
A short background on Biocon-BMS Research Center: BBRC is a BMS R&D center for Drug Discovery and Development in Bangalore, India with approximately 425 scientists. BBRC evolved from a simple outsourcing model started with Biocon in 1997 to a major strategic R&D site for BMS in emerging markets where new innovative medicines are discovered and developed for global diseases, such as Diabetes, Cancer, Rheumatoid Arthritis, and diseases of the Central Nervous System. The center has approximately 200,000 sq ft lab space with state of the art Vivarium and capabilities in Chemistry, Biology, Pharmaceutical Development, Animal models, Pharmacology, Toxicology and Bio-marker driven Targeted Medicines etc. BBRC distinguishes itself by its highly innovative, entrepreneurial and vibrant culture and is making a significant impact both on R&D productivity for BMS and for R&D ecosystems in India.
Dr Jindal will be speaking on the following:
Increasing innovation and decreasing costs in R&D through advantages of the Indian market
1. The unique model of R&D in the joint Biocon-BMS R&D center in Bangalore
2. Making significant impacts on discovery and development of new medicines and in R&D econsystems in India
3. Leveraging on advantages India has to offer for R&D